Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Current Leases (2019 - 2026)

Agios Pharmaceuticals (AGIO) has disclosed Current Leases for 8 consecutive years, with $18.8 million as the latest value for Q1 2026.

  • For Q1 2026, Current Leases rose 9.36% year-over-year to $18.8 million; the TTM value through Mar 2026 reached $18.8 million, up 9.36%, while the annual FY2025 figure was $18.4 million, 9.6% up from the prior year.
  • Current Leases hit $18.8 million in Q1 2026 for Agios Pharmaceuticals, up from $18.4 million in the prior quarter.
  • Across five years, Current Leases topped out at $18.8 million in Q1 2026 and bottomed at $83000.0 in Q3 2022.
  • Average Current Leases over 5 years is $13.3 million, with a median of $15.4 million recorded in 2024.
  • Year-over-year, Current Leases tumbled 98.13% in 2022 and then skyrocketed 17567.47% in 2023.
  • Agios Pharmaceuticals' Current Leases stood at $13.7 million in 2022, then rose by 9.84% to $15.0 million in 2023, then rose by 11.81% to $16.8 million in 2024, then increased by 9.6% to $18.4 million in 2025, then rose by 2.25% to $18.8 million in 2026.
  • According to Business Quant data, Current Leases over the past three periods came in at $18.8 million, $18.4 million, and $18.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.